Lantheus Holdings, Inc. (NASDAQ:LNTH) Short Interest Down 13.3% in February

Lantheus Holdings, Inc. (NASDAQ:LNTH) was the target of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 6,340,000 shares, a decrease of 13.3% from the February 13th total of 7,310,000 shares. Approximately 9.5% of the company’s stock are short sold. Based on an average daily trading volume, of 902,000 shares, the days-to-cover ratio is presently 7.0 days.

Lantheus Stock Down 0.4 %

Shares of NASDAQ LNTH traded down $0.42 on Thursday, reaching $102.86. 68,758 shares of the company’s stock traded hands, compared to its average volume of 932,157. The business’s 50 day simple moving average is $92.54 and its two-hundred day simple moving average is $96.68. Lantheus has a 12 month low of $57.78 and a 12 month high of $126.89. The company has a market cap of $7.04 billion, a price-to-earnings ratio of 17.13 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Analysts forecast that Lantheus will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LNTH has been the subject of several research analyst reports. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities reiterated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Finally, Truist Financial lifted their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $132.86.

Insider Activity at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 64,109 shares of company stock valued at $6,110,806. 1.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Wilmington Savings Fund Society FSB purchased a new stake in shares of Lantheus during the 3rd quarter valued at about $25,000. Kestra Investment Management LLC purchased a new stake in Lantheus during the fourth quarter valued at approximately $27,000. Summit Securities Group LLC bought a new position in Lantheus in the 4th quarter worth $37,000. UMB Bank n.a. raised its stake in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after buying an additional 134 shares during the period. Finally, Parkside Financial Bank & Trust lifted its holdings in Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock valued at $76,000 after purchasing an additional 280 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.